Ann Houston Email

SVP, Head External Research & Innovation . Rallybio

Current Roles

Employees:
51
Revenue:
$7.8M
About
Rallybio is a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Since its launch in January 2018, Rallybio has built a portfolio of promising product candidates, which are now in development to address rare diseases in the areas of hematology, immuno-inflammation, and metabolism. The Company’s mission is being advanced by a team of highly experienced biopharma industry leaders with extensive research, development, and rare disease expertise. The Company’s lead product candidate, RLYB211, is in development for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT), a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns. Beyond RLYB211, Rallybio‘s portfolio includes RLYB212, which is in preclinical development to address a rare hematologic disease, and three preclinical protein therapeutics for the treatment of rare immuno-inflammatory diseases. The Company’s portfolio also includes a discovery-stage program targeting a rare metabolic disease, which is part of a joint venture with Exscientia. In addition to its current pipeline, Rallybio continues to focus substantial efforts on expanding its product portfolio. The Company is deploying its extensive development expertise and global relationships to access innovative therapies with the potential to transform the lives of patients with rare diseases through both partnerships and acquisitions. Headquartered in New Haven, Connecticut, with an additional location at the University of Connecticut’s Technology Incubation Program in Farmington, Connecticut, Rallybio continues to place considerable scientific resources behind the development of promising product candidates to deliver on its mission.
Rallybio Address
234 Church Street
New Haven, CT
United States

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.